Origimm (‘Origins of immunity’) is a biotech company that specializes in the discovery of antigens and dermatological drug targets. The company uses its proprietary technology that employs reverse functional screening to discover and develop breakthrough therapies for the prevention and treatment of skin microbiome-associated diseases such as acne vulgaris and other microbiome-associated infections.
R&D:Origimm's lead program is the development of immune therapy against Propionibacterium acnes to treat acne vulgaris. For further information please visit our website: www.origimm.com